Core Insights - ABC Arbitrage reported a net income of €25.1 million for the year 2025, with a return on equity (ROE) of 14.8% and earnings per share (EPS) of €0.42, reflecting a decrease in net income compared to 2024 [2][3] Financial Performance - Current operating income increased to €59.7 million in 2025 from €51.2 million in 2024, marking a growth of over 15% [3] - Net income decreased from €26.8 million in 2024 to €25.1 million in 2025, a decline of approximately 6.3% [3] - EPS fell from €0.45 in 2024 to €0.42 in 2025, a decrease of about 6.7% [3] - ROE decreased from 16.4% in 2024 to 14.8% in 2025, indicating a decline in profitability relative to equity [3] Market Context - The financial year 2025 was characterized by increased market volatility compared to 2024, influenced by geopolitical tensions and changes in U.S. trade policy [4] - Despite the volatility, the mergers and acquisitions sector stabilized and even saw an increase towards the end of the year [4] Group Activity - Assets under management as of March 1, 2026, were €245 million, which is below the Group's targets [4] - The ABCA Opportunities and ABCA Reversion funds achieved returns above 10%, but this was not enough to reverse the declining trend in assets under management [4] Distribution Policy - The total distribution for the 2025 financial year is projected to be €0.34 per share, with a payout ratio of approximately 81% and a yield of 6.3% based on the share price as of December 31, 2025 [4] - The Board plans to propose a final dividend of €0.04 per share at the Annual General Meeting, with intentions to revert to a semi-annual distribution starting in December 2026 [4] Future Outlook - The Group anticipates a significant increase in activity for 2026, with the average Business Activity Level reported to be 40% above the 2025 monthly average as of March 20, 2026 [5] - A new strategic plan, Momentum 2028, aims to enhance revenue diversification and increase assets under management, requiring cumulative investments of €15 million to €25 million over three years [5] - The Group confirms a minimum annual dividend of €0.30 with a payout ratio of 66% and is considering strengthening its equity base through optional payment of dividends in shares [5]

Core Viewpoint - Biotalys is preparing to publish its annual report and financial results for 2025 on April 29, 2026, to incorporate recent changes in management and ensure quality oversight in reporting [1][2]. Financial Position - The company has a cash runway until the end of May 2026 and is in discussions with existing and new investors for additional financing to support ongoing operations [3][10]. - No binding financing proposals have been secured yet, but the updated timeline is expected to facilitate progress in these discussions [3][11]. Upcoming Events - A webcast and conference call will be held on April 29, 2026, at 15:00 CEST, allowing stakeholders to engage with management [4]. - The Annual General Shareholders Meeting (AGM) is scheduled for May 29, 2026, at 10:00 CEST at the company's headquarters [6]. Company Overview - Biotalys is an AgTech company focused on developing protein-based biocontrol solutions for sustainable crop protection, utilizing its AGROBODY™ technology platform [7]. - The company aims to provide effective product candidates that address key crop pests and diseases across the entire value chain, from soil to plate [7].

Core Viewpoint - Idorsia Ltd is proposing three candidates for election to its Board of Directors at the upcoming Annual General Meeting, aiming to enhance the Board's expertise in biopharmaceutical innovation and strategic execution [1][12]. Board Composition - The nominees include Natalia Misciattelli and Gabriel Baertschi as independent members, and André C. Muller as a non-independent member [2]. - The proposed Board composition aims to strengthen leadership with extensive experience in global operations and biopharmaceutical innovation, ensuring continuity through deep company knowledge [3]. Candidate Profiles - **Natalia Misciattelli**: CEO of AAVantgarde Bio with over 25 years of experience in biotechnology, focusing on therapeutic platforms and corporate development [5][6]. - **Gabriel Baertschi**: CEO of Grünenthal with more than 20 years in the pharmaceutical industry, known for his expertise in commercial strategy and market expansion [7][8]. - **André C. Muller**: Former CEO of Idorsia, who has been integral to the company's development since its inception, bringing extensive knowledge of Idorsia's business and strategic direction [9][10]. Re-election of Current Board Members - The Board will also propose the re-election of Jean-Paul Clozel as Chairman, along with independent members Mathieu Simon and Sandy Mahatme, while Bart Filius will not stand for re-election [11][13]. Annual General Meeting Details - The Annual General Meeting is scheduled for May 6, 2026, where shareholders are encouraged to register their shares by April 27, 2026, to participate in the voting process [14].

Core Viewpoint - Apollo-managed funds have entered into agreements to acquire Nippon Sheet Glass Company, Limited for nearly $3.7 billion, marking Apollo's largest private equity investment in Japan to date [1]. Group 1: Transaction Details - The investment will support NSG's financial position and long-term growth, with principal lenders transitioning a portion of their loans to equity to enhance the company's balance sheet [2]. - The transaction is subject to NSG shareholder approval at the annual general meeting in late June and regulatory approvals, expected to be completed by around March 2027 [3][5]. Group 2: Company Positioning - NSG Group is positioned to capture increasing demand for energy-efficient architectural glass, advanced automotive glazing, and performance solar products, supported by Apollo's investment and strategic backing [3]. - NSG Group's diversified manufacturing platform and strong customer relationships are key assets in driving growth initiatives and investing in next-generation technologies [3]. Group 3: Strategic Insights - Apollo's investment reflects a commitment to NSG Group's long-term success, combining Apollo's operational expertise with NSG's manufacturing excellence [4]. - This partnership aims to reinforce NSG's financial position, invest in technology and personnel, and enhance the company's resilience in the glass manufacturing sector [4]. Group 4: Apollo's Investment History - This acquisition represents Apollo's fifth private equity investment in Japan, with previous investments including Panasonic Automotive Systems and Mitsubishi Chemical's businesses [4].

Company Overview - The Progressive Corporation is an Ohio-based insurance holding company that provides insurance for personal and commercial vehicles, motorcycles, boats, recreational vehicles, and homes across the United States [4]. Offering Details - The company announced the pricing of $500 million aggregate principal amount of its 4.60% Senior Notes due 2031 and $1 billion aggregate principal amount of its 5.15% Senior Notes due 2036 in an underwritten public offering [1]. - The 2031 notes were priced at 99.987% of par, while the 2036 notes were priced at 99.676% of par [1]. - Goldman Sachs & Co. LLC and TD Securities (USA) LLC are acting as joint bookrunners for the offering [1]. Regulatory Information - The offering is made pursuant to an effective registration statement on Form S-3, filed with the Securities and Exchange Commission on May 17, 2024 [2]. - The offering is conducted only by means of a prospectus supplement and the accompanying prospectus [2].

Core Viewpoint - LOBO Technologies Ltd. has announced a public offering expected to raise approximately $2 million to fund development programs and general corporate purposes [1][3]. Offering Details - The offering consists of 3,921,567 units, each unit includes one Class A ordinary share, one Series A warrant, and one Series B warrant [2]. - The public offering price per unit is set at $0.51, while pre-funded units are priced at $0.509 [2]. - Each Series A and Series B warrant has an exercise price of $0.561 per Class A ordinary share, immediately exercisable upon issuance and expiring two years after the issuance date [2]. - The offering is expected to close on or about March 25, 2026, pending customary closing conditions [3]. Use of Proceeds - The net proceeds from the offering will be utilized for development programs, working capital, and other general corporate purposes [3]. Company Overview - LOBO Technologies Ltd. is a manufacturer of electric mobility products, specializing in eco-friendly electric vehicles and home-used robotic products [6]. - The product range includes e-bicycles, electric motorcycles, e-tricycles, solar-powered vehicles, and smart products aimed at promoting sustainable transportation [6].

Core Viewpoint - Sol-Gel Technologies Ltd. has announced an underwritten offering of 459,112 ordinary shares at a price of $72.00 per share, aiming to raise approximately $33.1 million in gross proceeds before expenses [1]. Group 1: Offering Details - The offering is expected to close on or about March 25, 2026, subject to customary closing conditions [1]. - Participation in the offering includes both new and existing investors such as Great Point Partners, LLC, Trails Edge Capital Partners, and others [2]. - TD Cowen and LifeSci Capital are acting as joint book-running managers for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the continued development of SGT-610, including pre-commercialization activities and research and development, with the remainder allocated for working capital and general corporate purposes [3]. Group 3: Company Overview - Sol-Gel Technologies is a specialized dermatology company focused on innovative therapies for rare and serious skin diseases, with its lead candidate SGT-610 being developed for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome [7]. - SGT-610 is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor, which may offer an improved safety profile compared to oral hedgehog inhibitors [7]. - The company is also advancing SGT-210, an investigational topical EGFR inhibitor, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY® [7].

Core Insights - DR H has launched the WUJI Smart Ring, a product that merges technology with high fashion, redefining smart wearables [1][3] Product Design - The WUJI Smart Ring features a fine jewelry design, created in collaboration with aesthetic director Alan Chan, incorporating a polished or brushed 925 silver base and a 60-facet briolette centerpiece with 24 gems [3] - The design philosophy combines Eastern symmetry and modern elegance, inspired by the concept of "Heaven Round, Earth Square" [3] - The ring is available in three colors: Silver, Azure, and Ruby, and aims to transform health management into a stylish lifestyle for modern women [3] Health Tracking Features - The WUJI Smart Ring offers comprehensive health tracking capabilities, including heart rate, nighttime blood oxygen, body temperature, menstrual cycles, and multidimensional sleep analysis [5] - It supports nearly 10 fitness modes, such as social dancing, Pilates, and yoga, integrating health monitoring with an upscale lifestyle [5] Health Management Ecosystem - DR H's DR HHH App includes a personalized health management tool called "TAIJI Girl," which provides daily tips based on over a million journal sources [7] - The app also offers mindfulness, sleep aids, and counseling services, creating a comprehensive health ecosystem [7] Market Positioning - The WUJI Smart Ring represents a new category of tech jewelry, aiming to elevate the sophistication and emotional value of wearable technology [9] - DR H plans to expand the aesthetic boundaries of smart wearables by introducing more design variations in the future [8]

Core Viewpoint - Boralex Inc. is conducting a strategic review of alternatives, with a special committee formed by the Board of Directors to evaluate and recommend options, although there is no guarantee that this will lead to a transaction [1] Company Overview - Boralex has been providing affordable renewable energy for over 35 years and is a leader in the Canadian market, as well as the largest independent producer of onshore wind power in France [3] - The company has facilities in the United States and the United Kingdom, and its installed capacity has increased by over 50% in the past five years, reaching 3,783 MW as of December 31, 2025 [3] - Boralex is developing a portfolio of projects totaling 8.2 GW in wind, solar, and Battery Energy Storage Systems (BESS), guided by corporate social responsibility values [3] - The company has been recognized as the Best Corporate Citizen in Canada by Corporate Knights and is actively participating in the fight against global warming [3] - Boralex's shares are listed on the Toronto Stock Exchange under the ticker symbol BLX [3]

Core Points - Traction Uranium Corp. announced the partial conversion and repayment of unsecured convertible debentures totaling C$450,000 out of a total principal amount of C$500,000 [1] - The company issued 1,071,429 units at a conversion price of $0.42 per unit, with each unit consisting of one common share and one warrant [2] - Each warrant allows the holder to acquire one common share at an exercise price of $0.55 for a period of 24 months from issuance [2] Company Overview - Traction Uranium Corp. is engaged in mineral exploration and development, focusing on uranium projects in Canada, including the Athabasca Region and the Aurora Project in partnership with Cosa Resources Corp. [5]